Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial.
A. Dickens (Singapore, Singapore), D. Halpin (Exeter, United Kingdom), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), K. Beeh (Wiesbaden, Germany), J. Chalmers (Dundee, United Kingdom), A. Clark (Norwich, United Kingdom), N. Hannan (Dunstable, United Kingdom), A. Kaplan (Stouffville, Toronto, Canada), K. Kostikas (Ioannina, Greece), H. Pinnock (Edinburgh, United Kingdom), N. Roche (Paris, France), O. Usmani (London, United Kingdom), J. Boven (Groningen, Netherlands), P. Mastoridis ( East Hanover, New Jersey, United States), K. Mezzi (Basel, Switzerland), S. Davis ( Leeds, West Yorkshire, United Kingdom), D. Price (Singapore, Singapore)
Source: International Congress 2022 – Asthma and COVID-19 management in primary care
Session: Asthma and COVID-19 management in primary care
Session type: Thematic Poster
Number: 515
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Dickens (Singapore, Singapore), D. Halpin (Exeter, United Kingdom), V. Carter (Singapore, Singapore), D. Skinner (Singapore, Singapore), K. Beeh (Wiesbaden, Germany), J. Chalmers (Dundee, United Kingdom), A. Clark (Norwich, United Kingdom), N. Hannan (Dunstable, United Kingdom), A. Kaplan (Stouffville, Toronto, Canada), K. Kostikas (Ioannina, Greece), H. Pinnock (Edinburgh, United Kingdom), N. Roche (Paris, France), O. Usmani (London, United Kingdom), J. Boven (Groningen, Netherlands), P. Mastoridis ( East Hanover, New Jersey, United States), K. Mezzi (Basel, Switzerland), S. Davis ( Leeds, West Yorkshire, United Kingdom), D. Price (Singapore, Singapore). Patient-reported barriers to accepting a technological adherence package in the MAGNIFY trial.. 515
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|